Skip to content

Comparison of aggressive versus standard intravenous hydration for clinical improvement in mild acute pancreatitis patient: A randomized controlled trial

Comparison of aggressive versus standard intravenous hydration for clinical improvement in mild acute pancreatitis patient: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210223008
Enrollment
44
Registered
2021-02-23
Start date
2019-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient presented with acute pancreatitis mild severity Mild acute pancreatitis

Interventions

The aggressive group receive Ringer lactate solution 20 ml/kg bolus then 3 ml/kg/hr. ,The standard group received Ringer lactate solution 10 ml/kg bolus then 1.5 ml/kg/hr.
Experimental Other,Experimental Other
Aggressive intravenous hydration protocol,Standard intravenous hydration protocol

Sponsors

Department of medicine, Phramongkutklao hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients aged >18 years who admitted to emergency department were diagnosed acute pancreatitis using Revised Atlanta classification defined by two of three following criteria: (1) epigastric abdominal pain, (2) elevated serum amylase and/or lipase greater than 3 times the upper limit of normal, (3) characteristic findings from abdominal imaging.

Exclusion criteria

Exclusion criteria: Exclusion criteria included advanced aged greater than 80 years old, New York Heart Association Class II or greater heart failure, active myocardial ischemia, cardiovascular intervention within previous 60 days, history of cirrhosis, renal insufficiency with creatinine clearance 2 mg/dl). Patients with history of metastasis malignancy, autoimmune disease, chronic infectious disease including human immunodeficiency virus or tuberculosis were excluded because of potential confounding related to inflammatory markers.

Design outcomes

Primary

MeasureTime frame
Clinical improvement 36 hours decrease in hematocrit, BUN, and serum creatinine from baseline, decrease in epigastric pain level and tolerance of oral intake.

Secondary

MeasureTime frame
development of SIRS 36 hours at least two of the following heart rate 90, WBC 12000, RR 20 Temp 38 C,development of severe pancreatitis 36 hours by Revised Atlanta classification,complication from volume overload 36 hours Clinical and physical examination and imaging,Relief of epigastric pain 36 hours VAS scores

Countries

Thailand

Contacts

Public ContactApirat Angsubhakorn

Phramongkutklao hospital

Angsubhakorn.api7@gmail.com0892279877

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026